S&P 500   4,298.06 (+0.37%)
DOW   33,716.27 (-0.14%)
QQQ   357.08 (+0.69%)
AAPL   184.44 (+1.93%)
MSFT   338.04 (+0.79%)
META   273.90 (+0.47%)
GOOGL   126.74 (+1.66%)
AMZN   124.91 (+0.53%)
TSLA   218.66 (+2.19%)
NVDA   391.69 (-0.40%)
NIO   7.78 (+2.91%)
BABA   83.96 (-0.37%)
AMD   119.00 (+0.97%)
T   15.38 (+1.12%)
F   12.65 (+2.10%)
MU   68.09 (-1.56%)
CGC   0.79 (-4.47%)
GE   104.81 (-0.94%)
DIS   90.32 (-0.50%)
AMC   4.62 (+1.54%)
PFE   38.78 (+1.09%)
PYPL   64.81 (+1.33%)
NFLX   410.64 (+2.54%)
S&P 500   4,298.06 (+0.37%)
DOW   33,716.27 (-0.14%)
QQQ   357.08 (+0.69%)
AAPL   184.44 (+1.93%)
MSFT   338.04 (+0.79%)
META   273.90 (+0.47%)
GOOGL   126.74 (+1.66%)
AMZN   124.91 (+0.53%)
TSLA   218.66 (+2.19%)
NVDA   391.69 (-0.40%)
NIO   7.78 (+2.91%)
BABA   83.96 (-0.37%)
AMD   119.00 (+0.97%)
T   15.38 (+1.12%)
F   12.65 (+2.10%)
MU   68.09 (-1.56%)
CGC   0.79 (-4.47%)
GE   104.81 (-0.94%)
DIS   90.32 (-0.50%)
AMC   4.62 (+1.54%)
PFE   38.78 (+1.09%)
PYPL   64.81 (+1.33%)
NFLX   410.64 (+2.54%)
S&P 500   4,298.06 (+0.37%)
DOW   33,716.27 (-0.14%)
QQQ   357.08 (+0.69%)
AAPL   184.44 (+1.93%)
MSFT   338.04 (+0.79%)
META   273.90 (+0.47%)
GOOGL   126.74 (+1.66%)
AMZN   124.91 (+0.53%)
TSLA   218.66 (+2.19%)
NVDA   391.69 (-0.40%)
NIO   7.78 (+2.91%)
BABA   83.96 (-0.37%)
AMD   119.00 (+0.97%)
T   15.38 (+1.12%)
F   12.65 (+2.10%)
MU   68.09 (-1.56%)
CGC   0.79 (-4.47%)
GE   104.81 (-0.94%)
DIS   90.32 (-0.50%)
AMC   4.62 (+1.54%)
PFE   38.78 (+1.09%)
PYPL   64.81 (+1.33%)
NFLX   410.64 (+2.54%)
S&P 500   4,298.06 (+0.37%)
DOW   33,716.27 (-0.14%)
QQQ   357.08 (+0.69%)
AAPL   184.44 (+1.93%)
MSFT   338.04 (+0.79%)
META   273.90 (+0.47%)
GOOGL   126.74 (+1.66%)
AMZN   124.91 (+0.53%)
TSLA   218.66 (+2.19%)
NVDA   391.69 (-0.40%)
NIO   7.78 (+2.91%)
BABA   83.96 (-0.37%)
AMD   119.00 (+0.97%)
T   15.38 (+1.12%)
F   12.65 (+2.10%)
MU   68.09 (-1.56%)
CGC   0.79 (-4.47%)
GE   104.81 (-0.94%)
DIS   90.32 (-0.50%)
AMC   4.62 (+1.54%)
PFE   38.78 (+1.09%)
PYPL   64.81 (+1.33%)
NFLX   410.64 (+2.54%)
NASDAQ:EWTX

Edgewise Therapeutics (EWTX) Stock Forecast, Price & News

$9.51
-0.19 (-1.96%)
(As of 12:39 PM ET)
Compare
Today's Range
$9.45
$9.65
50-Day Range
$5.71
$10.12
52-Week Range
$5.53
$14.33
Volume
22,775 shs
Average Volume
168,326 shs
Market Capitalization
$601.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Edgewise Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
78.8% Upside
$17.00 Price Target
Short Interest
Bearish
11.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$101,789 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.66) to ($2.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

855th out of 980 stocks

Pharmaceutical Preparations Industry

428th out of 485 stocks


EWTX stock logo

About Edgewise Therapeutics (NASDAQ:EWTX) Stock

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Receive EWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EWTX Stock News Headlines

Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 5.6%
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
RBC Capital Sticks to Their Buy Rating for Edgewise Therapeutics (EWTX)
See More Headlines

EWTX Price History

EWTX Company Calendar

Last Earnings
11/10/2021
Today
6/05/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EWTX
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$29.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+78.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-67,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.48 per share

Miscellaneous

Free Float
43,061,000
Market Cap
$601.78 million
Optionable
Not Optionable
Beta
-0.13

Key Executives

  • Dr. Kevin Koch Ph.D. (Age 63)
    Pres, CEO & Director
    Comp: $845.33k
  • Dr. Badreddin Edris Ph.D. (Age 36)
    Co-Founder & Independent Director
    Comp: $36.26k
  • Dr. Behrad Derakhshan Ph.D. (Age 43)
    Chief Bus. Officer
    Comp: $575.53k
  • Dr. Joanne M. Donovan M.D. (Age 66)
    Ph.D., Chief Medical Officer
    Comp: $556.23k
  • Dr. Alan J. Russell Ph.D. (Age 53)
    Co-Founder, Chief Scientific Officer & Director
  • Mr. R. Michael Carruthers (Age 65)
    Chief Financial Officer
  • Mr. John R. Moore (Age 59)
    Gen. Counsel
  • Dr. Marc Semigran M.D. (Age 66)
    Chief Devel. Officer













EWTX Stock - Frequently Asked Questions

Should I buy or sell Edgewise Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EWTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EWTX, but not buy additional shares or sell existing shares.
View EWTX analyst ratings
or view top-rated stocks.

What is Edgewise Therapeutics' stock price forecast for 2023?

3 analysts have issued twelve-month price targets for Edgewise Therapeutics' stock. Their EWTX share price forecasts range from $5.00 to $29.00. On average, they predict the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 78.8% from the stock's current price.
View analysts price targets for EWTX
or view top-rated stocks among Wall Street analysts.

How have EWTX shares performed in 2023?

Edgewise Therapeutics' stock was trading at $8.94 at the start of the year. Since then, EWTX stock has increased by 6.4% and is now trading at $9.51.
View the best growth stocks for 2023 here
.

When is Edgewise Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our EWTX earnings forecast
.

How were Edgewise Therapeutics' earnings last quarter?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.05.

When did Edgewise Therapeutics IPO?

(EWTX) raised $150 million in an initial public offering on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow acted as the underwriters for the IPO.

What is Edgewise Therapeutics' stock symbol?

Edgewise Therapeutics trades on the NASDAQ under the ticker symbol "EWTX."

Who are Edgewise Therapeutics' major shareholders?

Edgewise Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (12.55%), BlackRock Inc. (4.54%), Geode Capital Management LLC (1.23%), Granahan Investment Management LLC (1.16%), State Street Corp (1.04%) and American Century Companies Inc. (0.80%). Insiders that own company stock include Alan J Russell, Behrad Derakhshan, Holdings A/S Novo, James E Flynn, Joanne M Donovan, John R Moore, Jonathan D Root, Kevin Koch, Orbimed Advisors Llc, Peter A Thompson and R Michael Carruthers.
View institutional ownership trends
.

How do I buy shares of Edgewise Therapeutics?

Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edgewise Therapeutics' stock price today?

One share of EWTX stock can currently be purchased for approximately $9.51.

How much money does Edgewise Therapeutics make?

Edgewise Therapeutics (NASDAQ:EWTX) has a market capitalization of $601.78 million. The company earns $-67,640,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

How can I contact Edgewise Therapeutics?

Edgewise Therapeutics' mailing address is 3415 COLORADO AVE., BOULDER CO, 80303. The official website for the company is www.edgewisetx.com. The company can be reached via phone at 720-262-7002 or via email at ir@edgewisetx.com.

This page (NASDAQ:EWTX) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -